



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/522,207	10/27/2005	Mezher Hussein Ali	AC-22-US	3699
50446 7590 12/08/2008 HOXIE & ASSOCIATES LLC 75 MAIN STREET, SUITE 301 MILLBURN, NJ 07041				
EXAMINER				
CHANG, CELIA C				
ART UNIT		PAPER NUMBER		
1625				
MAIL DATE		DELIVERY MODE		
12/08/2008		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/522,207

Applicant(s)

ALI ET AL.

Examiner

Celia Chang

Art Unit

1625

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 28 September 2008.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-11 and 13-30 is/are pending in the application.
- 4a) Of the above claim(s) 15-30 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-11, 13-14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)


- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/S508)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

1. Applicant's election with traverse of group I, species of page 15 example 1 on Aug. 28, 2008 is acknowledged. The traversal is on the ground that the examiner cannot use compounds with different stereo-configuration for anticipation when the claims have stereo-limitation. This is not found persuasive because the claims used “....” or “◀” in the structural formula. It is well recognized in the chemical art that stereo-limitations are defined by the “S” or “R” configuration at a chiral center. The “....” or “◀” notation is not stereo limitation but up and down from the ring. Because six membered ring systems have equatorial/axial orientation, the up and down arrows do not offer any stereo-limitation. For example see the following structures from CAS:


RI 444987-55-4 CASPUS
CR Benzoic acid, N-[(1R)-1-(piperidin-1-yl)-4-[[[(2S,3R,4R,5S)-2,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]methoxy]]- (CA 154836 8A(6))

Absolute stereochemistry.



RI 64920-54-3 CASPUS
CR Benzoic acid, N-[(1R)-1-(4-(2,4-dichlorophenyl)ethyl)-6-[[[(2S,3R,4R,5S)-2,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]methoxy]]- (CA 159264 10(6))

Absolute stereochemistry.



It is evidenced that either “....” or “◀” can represent “S” or “R”. The particular stereo configuration can only be limited when the “S” or “R” is named at the chiral centers. The claims are therefore without stereo limitation and the anticipation was proper.

The requirement is still deemed proper and is therefore made FINAL.

Claim 12 has been canceled. Claims 3-6, 11 and claims 1-2, 7-10, 13-14 reading on formula I wherein R is C₁₋₃AlkylAr¹, Ar¹ is substituted phenyl is prosecuted. Claims 15-30 and the remaining subject matter of claims 1-2, 7-10, 13-14 are withdrawn from consideration per C37 CFR 1.142(b).

2. Claims 1-10, 13-14 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The claims used “....” or “◄” in the structural formula. It is well recognized in the chemical art that stereo-limitations are defined by the “S” or “R” configuration at a chiral center. The “....” or “◄” notation is not stereo limitation but up and down from the ring. Because six membered ring systems have axial orientation, the up and down arrows do not offer any stereo-limitation. Stereo-limitation is properly made as seen in the above CAS delineation that the proper “R” or “S” notation at each chiral center must be placed.

The following rejections of 102 or 103(a) are made based on none stereo limited formula I as claimed.

3. Claims 1-11, 13-14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The term “prodrug” was not defined or what kind of prodrug was disclosed in the specification. It is well recognized that prodrug is an unpredictable preparation of the lead compound wherein the “prodrug” is inactive and depend solely on the activity being release in vivo of the lead compound. Nowhere in the specification provided sufficient information as to what kind of modification of the drug functional groups as to result in an inactive prodrug which will be released into the active form in vivo.

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-10, 13-14 are rejected under 35 U.S.C. 102(b) as being anticipated by
Boeshagen et al. CA 113:126581, see RN attached; Ezure et al. CA 116:236093, RN 141206-

38-4; Brock et al. CA 119:96007, RN 149302-52-3, RN 149302-53-4; Berg et al. RN 8117-43-3; Kurihara et al. CA 114:185939 RN 133342-47-9; when the “...” or “◀” of the formula placed no limitation for the “R” or “S” configuration of the chiral center.

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1-11, 13-14 are rejected under 35 U.S.C. 103(a) as being unpatentable over Boeshagen et al. CA 113:126581, see RN attached; Ezure et al. CA 116:236093, RN 141206-38-4; Brock et al. CA 119:96007, RN 149302-52-3, RN 149302-53-4; Berg et al. RN 8117-43-3; Kurihara et al. CA 114:185939 RN 133342-47-9 in view of US 5,051,407, US 7,256,005 and Kato et al.

Determination of the scope and content of the prior art (MPEP §2141.01)

Boeshagen et al. CA 113:126581, Ezure et al. CA 116:236093, Brock et al. CA 119:96007, Berg et al. Kurihara et al. CA 114:185939 disclosed biological active hydroxymethyl-piperidinyltriol compounds having the same molecular formula as the claims.

Ascertainment of the difference between the prior art and the claims (MPEP §2141.02)

The difference between the species exemplified and the instant claims is the stereo-arrangement of the hydroxymethyl and the triol groups. Not only the patent disclosed the CA recited compounds i.e. US 5,051,407 or EP 536,402 taught that all variations of stereo arrangements are biologically active (see generic formula without stereo limitation); but also explicitly recognized in the biologically active piperidinyltriol art that all enantiomers of the triols are active and the activity differ only by degree.

Finding of prima facie obviousness—rational and motivation (MPEP§2142-2143)

One having ordinary skill in the art in possession of the above references would be in possession of the instant claims because the particular molecular structure has been available to one having ordinary skill. The modification of one enantiomer to another is a routine skill to one in the field (see Kato et al. whole article). The knowledge that enantiomers are all active but with different degree of activity would have motivated one having ordinary skill to prepare all enantiomers with the expectation that all compounds are active and some may be better or more selective in certain enzyme systems than others. In absence of unexpected results, preparation of stereo-isomer unexemplified from the generic formula is prima facie obvious picking some among many. Especially, the US 7,256,005 taught the variation of active stereo modification (see col. 7-8) and the Kato et al. taught that such variations are biologically active.

7. Claims 1-11, 13-14 are provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11, 13-14 of copending Application No. 10/522,208 or 10/586,188 in view of US 5,051,407 or EP 536,402 and Brine et al. or Kato et al.

The same rational of finding the stereo-modification based on analogous activity as delineated supra in section 5 is also applicable and incorporated by reference here.

This is a provisional obviousness-type double patenting rejection.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celia Chang, Ph. D. whose telephone number is 571-272-0679. The examiner can normally be reached on Monday through Thursday from 8:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres, Ph. D., can be reached on 571-272-0867. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

OACS/Chang
Dec. 3, 2008

/Celia Chang/
Primary Examiner
Art Unit 1625